TY - JOUR
T1 - Longitudinal analysis of anti-drug antibody development in multiple sclerosis patients treated with interferon beta-1a (Rebif™) using B cell receptor repertoire analysis
AU - van der Weele, Linda
AU - Pollastro, Sabrina
AU - van Schaik, Barbera D. C.
AU - van Kampen, Antoine H. C.
AU - Niewold, Ilse T. G.
AU - Kuijpers, Taco W.
AU - Warnke, Clemens
AU - Jensen, Poul Erik H.
AU - Kramer, Daniel
AU - Ryner, Malin
AU - Hermanrud, Christina
AU - Dönnes, Pierre
AU - Pallardy, Marc
AU - Spindeldreher, Sebastian
AU - on behalf of the ABIRISK Consortium
AU - Deisenhammer, Florian
AU - Fogdell-Hahn, Anna
AU - de Vries, Niek
N1 - Funding Information: The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking ABIRISK project under grant agreement n° 115303, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.The research leading to these results was conducted as part of the ABIRISK consortium (Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk). For further information, please refer to www.abirisk.eu. This work was carried out on the Dutch national e-infrastructure with the support of SURF Foundation (e-infra180005). Funding Information: AFH has received unrestricted funding from Biogen Idec, Pfizer, Orion Pharma and Celltrion, speaking honoraria from Merck, and consulting fee from Roche. Funding Information: The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking ABIRISK project under grant agreement n° 115303 , resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme ( FP7/2007-2013 ) and EFPIA companies’ in kind contribution. Publisher Copyright: © 2022
PY - 2022/9/15
Y1 - 2022/9/15
N2 - A significant proportion of multiple sclerosis (MS) patients treated with interferon beta-1a (Rebif™) develop anti-drug antibodies (ADA) with a negative impact on treatment efficacy. We hypothesized that high-throughput B-cell receptor (BCR) repertoire analysis could be used to predict and monitor ADA development. To study this we analyzed 228 peripheral blood samples from 68 longitudinally followed patients starting on interferon beta-1a. Our results show that whole blood BCR analysis does not reflect, and does not predict ADA development in MS patients treated with interferon beta-1a. We propose that BCR analysis of phenotypically selected cell subsets or tissues might be more informative.
AB - A significant proportion of multiple sclerosis (MS) patients treated with interferon beta-1a (Rebif™) develop anti-drug antibodies (ADA) with a negative impact on treatment efficacy. We hypothesized that high-throughput B-cell receptor (BCR) repertoire analysis could be used to predict and monitor ADA development. To study this we analyzed 228 peripheral blood samples from 68 longitudinally followed patients starting on interferon beta-1a. Our results show that whole blood BCR analysis does not reflect, and does not predict ADA development in MS patients treated with interferon beta-1a. We propose that BCR analysis of phenotypically selected cell subsets or tissues might be more informative.
KW - Adaptive immune receptor repertoire
KW - Anti-drug antibody
KW - B-cell receptor
KW - Interferon beta
KW - Multiple sclerosis
KW - Next generation sequencing
UR - http://www.scopus.com/inward/record.url?scp=85134403648&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jneuroim.2022.577932
DO - https://doi.org/10.1016/j.jneuroim.2022.577932
M3 - Article
C2 - 35853357
SN - 0165-5728
VL - 370
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
M1 - 577932
ER -